Stockscreener 앱 받기
40.85
0.15%
0.06
시간 외 거래:
40.85
Alkermes Plc 주식(ALKS)의 최신 뉴스
Alkermes plc Hired Firms, 2011 - OpenSecrets
Alkermes: Idiopathic Hypersomnia Could Expand LUMRYZ Into A Larger Growth, Margin Driver - Seeking Alpha
Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works? - Insider Monkey
Alkermes Must Face Bulk Of Addiction Treatment Drug Suit - Law360
Alkermes Fails to Fend Off Addiction Treatment Antitrust Claim - Bloomberg Law News
Alkermes plc (AKD.DE) Analyst Insights, Price Targets & RecommendationsYahoo Finance - Yahoo! Finance Canada
Alkermes PLC (ALKS) Shares Fall 3.2% -- GF Value Says Still Over - GuruFocus
ALKS Reinstated by Goldman Sachs -- Rating Set to Neutral - GuruFocus
Alkermes plc (ALKS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Goldman Sachs resumes Alkermes stock coverage with neutral rating - Investing.com
ALKS Looks 29.1% Overvalued on GF Value™ - GuruFocus
Alkermes Says Experimental Drug Could Open New Path in ADHD Treatment - Yahoo
Alkermes: The Orexin Upside Is Real, But Takeda And Lilly Stand In The Way (Downgrade) - Seeking Alpha
Why Alkermes (ALKS) Is Down 6.0% After First ADHD Data For Orexin Agonist ALKS 7290 - Yahoo Finance
Annual Research Grant Program Expands Focus to Include Narcolepsy - sleepreviewmag.com
ALKS News | ALKERMES PLC (NASDAQ:ALKS) - ChartMill
ALKS Reiterated by RBC Capital -- Price Target Maintained at $56 - GuruFocus
ALKS Maintains by Baird -- Price Target Raised to $61.00 - GuruFocus
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290 - finance.yahoo.com
Alkermes reports positive top-line Phase Ib trial data for ALKS 7290 - Clinical Trials Arena
TD Cowen reiterates Alkermes stock Buy rating on ADHD trial data - Investing.com Australia
Form 8K Alkermes plc. For: 21 September By Investing.com - ng.investing.com
Alkermes Shares Jump 6.5% After ADHD Drug Shows Clinical Proof-of-Concept - finance.biggo.com
ALKS Looks 34.7% Overvalued on GF Value™ - GuruFocus
Alkermes' ALKS7290 shows strong early results i... - pluang.com
ALKS Reiterates by Needham -- Price Target Maintained at $62.00 - GuruFocus
Alkermes Announces Positive Phase 1 Topline Results for ALKS 7290 in ADHD Treatment - Kalkine Media
Stifel reiterates Alkermes stock rating on ADHD drug trial data By Investing.com - Investing.com Australia
Alkermes reports positive phase 1 data for ADHD drug candidate By Investing.com - Investing.com Australia
ALKS Looks 33.1% Overvalued on GF Value™ as ADHD Drug Shows Earl - GuruFocus
Alkermes rises on phase 1 results for ADHD drug ALKS 7290 - Seeking Alpha
Alkermes Shares Rise 6.5% After Positive Phase 1b Results for ADHD Drug ALKS 7290 - Yahoo Finance
Why is Alkermes stock surging today? By Investing.com - Investing.com Canada
Alkermes stock jumps on positive ADHD drug trial results - Investing.com
Alkermes reports positive phase 1 data for ADHD drug candidate - Investing.com
Alkermes Announces Positive Phase 1b Results for ALKS 7290 in Adults With ADHD - TradingView
Alkermes plc: Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) - finanznachrichten.de
An ADHD drug in testing cut symptom scores by 19 points - stocktitan.net
Alkermes Plc (ALKS) Stock Analysis: A Look At Its 29.88% Potential Upside - DirectorsTalk Interviews
ALKS Looks 33.6% Overvalued on GF Value™ as Shares Drop to June Lows - GuruFocus
Alkermes PLC (ALKS) Shares Fall 7.1% -- What GF Score of 64 Tells Investors - GuruFocus
Alkermes Falls as Investors Appear to Take Profits Despite No Obvious Negative Company Update - Quiver Quantitative
Anne Clem Whitaker is director at Alkermes (NASDAQ: ALKS) with no reported holdings - stocktitan.net
Alkermes slides 7%, reaching multi-month low (ALKS:NASDAQ) - Seeking Alpha
Alkermes Strengthens Board with New Director Appointment - The Globe and Mail
REGBlackRock GroupSAR 6ALKERMES PLC - TradingView
Form 8K Alkermes plc. For: 16 September By Investing.com - Investing.com Nigeria
Alkermes Expands Board with Anne C. Whitaker Appointment and Details Compensation Package - Kalkine Media
Alkermes Appoints Anne C. Whitaker to Board of Directors - citybiz
New Alkermes (NASDAQ: ALKS) director to get $600,000 in stock awards - stocktitan.net
Alkermes Announces Appointment of Anne C. Whitaker to Board of D - GuruFocus
Alkermes appoints Anne Whitaker to board of directors By Investing.com - Investing.com Nigeria
ALKS Looks 42.0% Overvalued on GF Value™ - GuruFocus
Alkermes appoints Anne Whitaker to board of directors - Investing.com
Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors - Lelezard
Alkermes: A Slow-Burning Buy Prospect On Orexin-Agonist Promise (NASDAQ:ALKS) - Seeking Alpha
Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program - Business Wire
After two decades at Alkermes, a biotech CFO joins Tortugas’ board - Stock Titan
Responsive Playbooks and the ALKS Inflection - Stock Traders Daily
0.18%
0.69%
자본화:
|
볼륨(24시간):